Clinical Trial Update: Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a trastuzumab biosimilar (Samfenet) plus physician's choice therapy for HER2-positive solid tumors. Status and results are not disclose…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Samfenet (trastuzumab biosimilar)

Snippet

Sponsor: Jin-Hee Ahn | Conditions: HER-2 Protein Overexpression, HER-2 Gene Amplification | Phase 2 | Status: UNKNOWN